@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix go: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix hasAgent: . @prefix obo: . @prefix occursIn: . @prefix do: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasAgent: sub:_2; a go:0016301 . sub:_2 geneProductOf: hgnc:1771; a Protein: . sub:_3 occursIn: do:1324, obo:CLO_0007986, obo:UBERON_0002048, species:9606; rdf:object sub:_1; rdf:predicate belv:decreases; rdf:subject chebi:3722; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:cisplatin) -| kin(p(HGNC:CDK2))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "To directly measure cdk2 activity after cisplatin treatment, immunoprecipitated cdk2 kinase assays were performed. Consistent with the levels of pTyr15-cdk2 after cisplatin treatment in the absence of doxycycline, there was a 2.5-fold reduction in cdk2 kinase activity."; prov:wasQuotedFrom pubmed:19683496 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:19683496; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:36.118+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }